Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I

Molecular Genetics and Metabolism

Volumn 102, Issue 2, 2011, Pages 122-125

  Thimm, Eva ^a   Herebian, Diran ^a   Assmann, Birgit ^a   Klee, Dirk ^a   Mayatepek, Ertan ^a   Spiekerkoetter, Ute ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

HT1; Metabolic disorders; Nitsinone; NTBC

Indexed keywords

NEUROTRANSMITTER; NITISINONE; SEROTONIN; TYROSINE;

ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CHILD; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; HUMAN; MALE; MORPHOLOGY; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; SCHOOL CHILD; TYROSINEMIA; TYROSINEMIA TAYPE I; TYROSINEMIA TYPE I;

BRAIN; CHILD; CYCLOHEXANONES; ENZYME INHIBITORS; HUMANS; INFANT; MALE; NITROBENZOATES; PSYCHOMOTOR PERFORMANCE; SEROTONIN; TYROSINE; TYROSINEMIAS;

EID: 78651419741     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.11.003     Document Type: Article

References (33)

1. Mitchell G., Grompe M., Lambert M., Tanguay R. Hypertyrosinemia. The metabolic and molecular bases of inherited disease 2001, 1777-1805. McGraw-Hill. C. Scriver, A. Beaudet, W. Sly, D. Valle (Eds.).
2. van Spronsen F., Smit G., Wijburg F., Thomasse Y., Visser G., Heymans H. Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. J. Inherit. Metab. Dis. 1995, 18:111-114.
3. Lindstedt S., Holme E., Lock E., Hjalmarson O., Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992, 3:813-817.
4. Holme E., Lindstedt S. Nontransplant treatment of tyrosinemia. Clin. Liver Dis. 2000, 4:805-814.
5. Masurel-Paulet A., Poggi-Bach J., Rolland M., Bernard O., Guffon N., Dobbelaere D., Sarles J., de Baulny H., Touati G. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J. Inherit. Metab. Dis. 2008, 31:81-87.
6. Bonnet L., Bonnemoy F., Dusser M., Bohatier J. Toxicity assessment of the herbicides sulcotrione and mesotrione toward two reference environmental microorganisms: Tetrahymena pyriformis and Vibrio fischeri. Arch. Environ. Contam. Toxicol. 2008, 55:576-583.
7. Holme E., Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione). J. Inherit. Metab. Dis. 1998, 21:507-517.
8. Macsai M., Schwartz T., Hinkle D., Hummel M., Mulhern M., Rootman D. Tyrosinemia type II: nine cases of ocular signs and symptoms. Am. J. Ophthalmol. 2001, 132:522-527.
9. Ellaway C., Holme E., Standing S., Preece M., Green A., Ploechl E., Ugarte M., Trefz F., Leonard J. Outcome of tyrosinaemia type III. J. Inherit. Metab. Dis. 2001, 24:824-832.
10. Cerone R., Fantasia A., Castellano E., Moresco L., Schiaffino M., Gatti R. Pregnancy and tyrosinaemia type II. J. Inherit. Metab. Dis. 2002, 25:317-318.
11. Sgaravatti A., Vargas B., Zandoná B., Deckmann K., Rockenbach F., Moraes T., Monserrat J., Sgarbi M., Pederzolli C., Wyse A., Wannmacher C., Wajner M., Dutra-Filho C. Tyrosine promotes oxidative stress in cerebral cortex of young rats. Int. J. Dev. Neurosci. 2008, 26:551-559.
12. Sener R. Tyrosinemia: computed tomography, magnetic resonance imaging, diffusion magnetic resonance imaging, and proton spectroscopy findings in the brain. J. Comput. Assist. Tomogr. 2005, 29:323-325.
13. Sener R. Brain magnetic resonance imaging in tyrosinemia. Acta Radiol. 2005, 46:618-620.
14. Ris M., Weber A., Hunt M., Berry H., Williams S., Leslie N. Adult psychosocial outcome in early-treated phenylketonuria. J. Inherit. Metab. Dis. 1997, 20:499-508.
15. Burgard P. Development of intelligence in early treated phenylketonuria. Eur. J. Pediatr. 2000, 159:S74-S79.
16. Herebian D., Spiekerkoetter U., Lamshoeft M., Thimm E., Laryea M., Mayatepek E. Liquid chromatography tandem mass spectrometry method for the quantitation of NTBC (2-(nitro-4-trifluoromethylbenzoyl)1, 3-cyclohexanedione) in plasma of tyrosinemia type 1 patients. J. Chromatogr. B 2009, 877:1452-1459.
17. Bräutigam C., Wevers R., Jansen R., Smeitink J., de Rijk-van Andel J., Gabreëls F., Hoffmann G. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin. Chem. 1998, 44:1897-1904.
18. Fernstrom J., Fernstrom M. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J. Nutr. 2007, 137:1539S-1547S.
19. Güttler F., Lou H. Dietary problems of phenylketonuria: effect on CNS transmitterrs and their possible role in behaviour and neuropsychological function. J. Inherit. Metab. Dis. 1986, 9:S169-S177.
20. McKean C. The effects of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain. Brain Res. 1972, 12:469-476.
21. Lou H., Lykkelund C., Gerdes A., Udesen H., Bruhn P. Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr. Scand. 1987, 76:560-565.
22. Pratt O. Transport inhibition in the pathology of phenylketonuria and other inherited metabolic diseases. J. Inherit. Metab. Dis. 1982, 5:S75-S81.
23. Diamond A., Ciaramitaro V., Donner E., Djali S., Robinson M. An animal model of early-treated PKU. J. Neurosci. 1994, 5:3072-3082.
24. Pietz J., Landwehr R., Kutscha A., Schmidt H., de Sonneville L., Trefz F. Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria. J. Pediatr. 1995, 127:936-943.
25. Mazzocco M., Yannicelli S., Nord A., van Doorninck W., Davidson-Mundt A., Greene C. Cognition and tyrosine supplementation among school-aged children with phenylketonuria. Am. J. Dis. Child. 1992, 146:1261-1264.
26. Eisenberg J., Asnis G., van Praag H., Vela R. Effect of tyrosine on attention deficit disorder with hyperactivity. J. Clin. Psychiatry 1988, 49:193-195.
27. Gelenberg A., Wojcik J., Falk W., Baldessarini R., Zeisel S., Schoenfeld D., Mok G. Tyrosine for depression: a double-blind trial. J. Affect. Disord. 1990, 19:125-132.
28. Tam S., Roth R. Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions?. Biochem. Pharmacol. 1997, 21:441-453.
29. Lovenberg W., Jequier E., Sjoerdsma A. Tryptophan hydroxylation in mammalian systems. Adv. Pharmacol. 1968, 6:21-36.
30. Tong J., Kaufman S. Tryptophan hydroxylase. Purification and some properties of the enzyme from rabbit hindbrain. J. Biol. Chem. 1975, 250:4152-4158.
31. Savelieva K., Zhao S., Pogorelov V., Rajan I., Yang Q., Cullinan E., Lanthorn T. Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants. PLoS ONE 2008, 3:e3301.
32. Coon H., Dunn D., Lainhart J., Miller J., Hamil C., Battaglia A., Tancredi R., Leppert M., Weiss R., McMahon W. Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2). Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 135:42-46.
33. Sheehan K., Lowe N., Kirley A., Mullins C., Fitzgerald M., Gill M., Hawi Z. Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol. Psychiatry 2005, 10:944-949.